(IPN) Ipsen - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: PA (France) | Market Cap: 13.614m EUR | Total Return: 64.1% in 12m
Oncology Medicines, Rare Disease Drugs, Neuroscience Treatments
Total Rating 73
Safety 82
Buy Signal 0.10
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.3
Industry Rotation: -1.3
Market Cap:
15.9B
Avg Turnover: 16.2M
Avg Turnover: 16.2M
Risk 3d forecast
Volatility23.8%
VaR 5th Pctl4.02%
VaR vs Median2.44%
Reward TTM
Sharpe Ratio1.88
Rel. Str. IBD78.7
Rel. Str. Peer Group69.9
Character TTM
Beta0.212
Beta Downside0.186
Hurst Exponent0.590
Drawdowns 3y
Max DD29.25%
CAGR/Max DD0.53
CAGR/Mean DD1.41
Warnings
No concerns identified
Tailwinds
Confidence
Description: IPN Ipsen
Ipsen S.A. is a French biopharmaceutical firm specializing in oncology, rare diseases, and neuroscience. Its core oncology portfolio features Somatuline and Cabometyx, while its neuroscience division is centered on Dysport. The company maintains an active R&D pipeline with several assets in Phase II and Phase III clinical trials, including treatments for pediatric gliomas and follicular lymphoma.
The pharmaceutical industry operates on a high-margin research and development model where patent protections provide temporary exclusivity for specialized therapies. Ipsen utilizes a partnership strategy, such as its collaboration with Simcere Zaiming, to mitigate development risks and expand its geographical reach in the oncology sector.
For more detailed financial metrics and valuation analysis, consider exploring the data available on ValueRay.
- Somatuline revenue erosion accelerates as generic competition enters the European market
- Cabometyx label expansions drive oncology sales growth in international markets
- Rare disease portfolio diversification reduces historical dependence on core oncology assets
- R&D pipeline execution determines long-term valuation beyond current patent protection cycles
- Strategic acquisitions and licensing agreements deplete cash reserves to fuel growth pipeline
Piotroski VR‑10 (Strict)
8.5
| Net Income: 789.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 3.37 > 1.0 |
| NWC/Revenue: 19.09% < 20% (prev 10.59%; Δ 8.51% < -1%) |
| CFO/TA 0.30 > 3% & CFO 2.05b > Net Income 789.4m |
| Net Debt (-471.4m) to EBITDA (2.29b): -0.21 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.2m) vs 12m ago -0.61% < -2% |
| Gross Margin: 76.55% > 18% (prev 0.82%; Δ 7.57k% > 0.5%) |
| Asset Turnover: 108.4% > 50% (prev 75.67%; Δ 32.73% > 0%) |
| Interest Coverage Ratio: 26.79 > 6 (EBITDA TTM 2.29b / Interest Expense TTM 59.2m) |
Altman Z''
5.05
| A: 0.20 (Total Current Assets 2.82b - Total Current Liabilities 1.44b) / Total Assets 6.94b |
| B: 0.06 (Retained Earnings 443.5m / Total Assets 6.94b) |
| C: 0.24 (EBIT TTM 1.59b / Avg Total Assets 6.69b) |
| D: 1.85 (Book Value of Equity 4.82b / Total Liabilities 2.60b) |
| Altman-Z'' Score: 5.05 = AAA |
Beneish M
-2.97
| DSRI: 0.90 (Receivables 932.1m/697.2m, Revenue 7.25b/4.87b) |
| GMI: 1.08 (GM 76.55% / 82.42%) |
| AQI: 0.85 (AQ_t 0.50 / AQ_t-1 0.58) |
| SGI: 1.49 (Revenue 7.25b / 4.87b) |
| TATA: -0.18 (NI 789.4m - CFO 2.05b) / TA 6.94b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of IPN shares?
As of May 16, 2026, the stock is trading at EUR 166.00 with a total of 72,319 shares traded.
Over the past week, the price has changed by -0.24%, over one month by +1.97%, over three months by +6.68% and over the past year by +64.14%.
Over the past week, the price has changed by -0.24%, over one month by +1.97%, over three months by +6.68% and over the past year by +64.14%.
Is IPN a buy, sell or hold?
Ipsen has no consensus analysts rating.
What are the forecasts/targets for the IPN price?
| Analysts Target Price | - | - |
Ipsen (IPN) - Fundamental Data Overview
as of 15 May 2026
Market Cap USD = 15.95b (13.61b EUR * 1.1715 EUR.USD)P/E Trailing = 31.0526
P/E Forward = 18.315
P/S = 3.4647
P/B = 3.1625
P/EG = 1.1586
Revenue TTM = 7.25b EUR
EBIT TTM = 1.59b EUR
EBITDA TTM = 2.29b EUR
Long Term Debt = 834.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 136.3m EUR (from shortTermDebt, last quarter)
Debt = 1.05b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -471.4m EUR (from netDebt column, last quarter)
Enterprise Value = 13.14b EUR (13.61b + Debt 1.05b - CCE 1.53b)
Interest Coverage Ratio = 26.79 (Ebit TTM 1.59b / Interest Expense TTM 59.2m)
EV/FCF = 7.40x (Enterprise Value 13.14b / FCF TTM 1.78b)
FCF Yield = 13.51% (FCF TTM 1.78b / Enterprise Value 13.14b)
FCF Margin = 24.49% (FCF TTM 1.78b / Revenue TTM 7.25b)
Net Margin = 10.89% (Net Income TTM 789.4m / Revenue TTM 7.25b)
Gross Margin = 76.55% ((Revenue TTM 7.25b - Cost of Revenue TTM 1.70b) / Revenue TTM)
Gross Margin QoQ = 59.26% (prev 82.14%)
Tobins Q-Ratio = 1.89 (Enterprise Value 13.14b / Total Assets 6.94b)
Interest Expense / Debt = 1.94% (Interest Expense 20.4m / Debt 1.05b)
Taxrate = 28.79% (44.1m / 153.2m)
NOPAT = 1.13b (EBIT 1.59b * (1 - 28.79%))
Current Ratio = 1.96 (Total Current Assets 2.82b / Total Current Liabilities 1.44b)
Debt / Equity = 0.24 (Debt 1.05b / totalStockholderEquity, last quarter 4.34b)
Debt / EBITDA = -0.21 (Net Debt -471.4m / EBITDA 2.29b)
Debt / FCF = -0.27 (Net Debt -471.4m / FCF TTM 1.78b)
Total Stockholder Equity = 4.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.80% (Net Income 789.4m / Total Assets 6.94b)
RoE = 18.80% (Net Income TTM 789.4m / Total Stockholder Equity 4.20b)
RoCE = 31.51% (EBIT 1.59b / Capital Employed (Equity 4.20b + L.T.Debt 834.2m))
RoIC = 23.31% (NOPAT 1.13b / Invested Capital 4.84b)
WACC = 6.35% (E(13.61b)/V(14.67b) * Re(6.73%) + D(1.05b)/V(14.67b) * Rd(1.94%) * (1-Tc(0.29)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -0.79%
[DCF] Terminal Value 86.15% ; FCFF base≈1.64b ; Y1≈1.85b ; Y5≈2.51b
[DCF] Fair Price = 805.3 (EV 65.89b - Net Debt -471.4m = Equity 66.36b / Shares 82.4m; r=6.35% [WACC]; 5y FCF grow 15.13% → 3.0% )
EPS Correlation: -59.95 | EPS CAGR: -68.50% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.98 | Revenue CAGR: 12.83% | SUE: -0.12 | # QB: 0
EPS current Year (2026-12-31): EPS=13.76 | Chg30d=+3.08% | Revisions=+40% | GrowthEPS=+13.8% | GrowthRev=+9.8%
EPS next Year (2027-12-31): EPS=13.47 | Chg30d=+2.16% | Revisions=+60% | GrowthEPS=-2.1% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: +60%